Automated determination of clozapine and major metabolites in serum and urine

Therapeutic Drug Monitoring

Volumn 19, Issue 4, 1997, Pages 480-488

  Weigmann, Harald ^a   Bierbrauer, Jürgen ^a   Härtter, Sebastian ^a   Hiemke, Christoph ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Clozapine; Clozapine metabolism; Column switching; High performance liquid chromatography (HPLC); Serum Urine

Indexed keywords

CLOZAPINE; CLOZAPINE DERIVATIVE; CLOZAPINE N OXIDE; NEUROLEPTIC AGENT; NORCLOZAPINE; UNCLASSIFIED DRUG;

ARTICLE; AUTOANALYSIS; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCHIZOPHRENIA; ULTRAVIOLET RADIATION;

ANTIPSYCHOTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLOZAPINE; HUMANS; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY;

EID: 0031405756     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199708000-00020     Document Type: Article

References (56)

1. Ereshefsky L, Watanabe MD, Tran-Johnson TK. Clozapine: an atypical antipsychotic agent. Clin Pharm 1989;8:691-709.
2. Baldessarini RJ, Frankenburg FR. Clozapine a novel antipsychotic agent. New Engl J Med 1991;324:746-754.
3. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison versus chlorpromazine. Arch Gen Psychiatry 1988;45:789-796.
4. Creese I. Classical and atypical antipsychotic drugs: new insights. Trends in Neurosci 1983;6:479-480.
5. Meltzer HY, Bastani B, Young Kwonn K. A prospective study of clozapine in treatment resistant schizophrenic patients I. preliminary report. Psychopharmacology 1989;99:68-72.
6. Krupp P, Barnes P. Leponex-associated granulocytopenia: a review of the situation. Psychopharmacology 1989;99:118-121.
7. Perry PJ, Miller DD, Arndt SV, Cadoret RJ. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 1991;148: 231-235.
8. Hasegawa M, Gutierrez-Esteinou R, Way L, Meltzer HY. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. J Clin Psychopharmacol 1993;13:383-390.
9. Piscitelli SC, Frazier JA, McKenna K, et al. Plasma clozapine and haloperidol concentrations in adolescent with childhood-onset schizophrenia: association with response. J Clin Psychiatry 1994;55 (suppl B):94-97.
10. Potkin SG, Bera R, Gulasekaram B, et al. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry 1994;55 (Suppl. B):133-136.
11. Kronig MH, Munne RA, Szymanski S, et al. Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am J Psychiatry 1992;152:179-182.
12. Liu H-C, Chang W-H, Wei F-C, Lin S-K, Lin S-K, Jann MW. Monitoring of plasma clozapine levels and its metabolites in refractory schizophrenic patients. Ther Drug Monit 1996;18:200-207.
13. Haring C, Neudorfer C, Schwitzer J, et al. EEG alterations in patients treated with clozapine in relation to plasma levels. Psychopharmacology 1994;114:97-100.
14. Diesen OV, Thomsen K, Jensen PN, et al. Clozapine serum levels and side effects during steady state treatment of schizophrenic patients: a cross-sectional study. Psychopharmacology 1995;117: 371-378.
15. Kuoppamäki M, Syvälahti E, Hietala J. Clozapine and N-Desmethylclozapine are potent 5-HT1c receptor antagonists. Eur J Pharmacol - Molecular Pharmacology Section 1993;245:179-182.
16. Baldessarini RJ, Centorrino F, Flood JG, Volpicelli SA, Huston-Lyons D, Cohen BM. Tissue concentrations of clozapine and its metabolites in the rat. Neuropsychopharmacology 1993;9:117-124.
17. Veys PA, Wilkes S, Shah S, Noyelle R, Hofbrand AV. Clinical experience of clozapine-induced neutropenia in the UK. Drug Safety 1992;7 (suppl 1):26-32.
18. Gerson SL, Arce C, Meltzer HY. N-desmethylclozapine: a clozapine metabolite that suppresses haemopoiesis. Br J Haematol 1994;86:555-561.
19. Weigmann H, Hiemke C. Determination of clozapine and its major metabolites in human serum using automated solid-phase extraction and subsequent isocratic high-performance liquid chromatography with ultraviolet detection. J Chromatogr 1992;583:209-216.
20. Volpicelli SA, Centorrino F, Puopolo PR, et al. Determination of clozapine, norclozapine and clozapine-N-oxide in serum by liquid chromatography. Clin Chem 1993;39:1656-1659.
21. Schulz E, Fleischhaker H, Remschmidt H. Determination of clozapine and its major metabolites in serum samples of adolescent schizophrenic patients by high-performance liquid chromatography. Pharmacopsychiatry 1995;28:20-25.
22. Fadiran EO, Leslie J, Fossler M, Young D. Determination of clozapine and its major metabolites in human serum and rat plasma by liquid chromatography using solid-phase extraction and ultraviolet detection. J Pharm Biomed Anal 1995;13:185-190.
23. Gauch R, Michaelis W. The metabolism of 8-Chlor-11-(4-methyl-4-piperazinyl)-5H-dibenzo (b,c) (1,4) diazepine (clozapine) in mice, dogs and human subjects. Farmaco 1971;26:151-157.
24. Meier J. Bioanalytical assay of clozapine and its N-oxide metabolite and the determination of their blood levels in the dog. Brit J Pharmacol 1985;53:440.
25. Zeren W, Minglian L, Peipei X, Yanlin Z. Determination of clozapine and its metabolites in serum and urine by reversed phase HPLC. Biomed Chromatogr 1986;2:53-57.
26. Choc MG, Lehr RG, Hsuan F, et al. Multiple-dose pharmacokinetics of clozapine in patients. Pharm Res 1987:4:402-405.
27. Haring C, Humpel C, Auer B, et al. Clozapine plasma levels determined by high-performance liquid chromatography with ultraviolet detection. J Chromatogr 1988;428:160-166.
28. Humpel C, Haring C, Saria A. Rapid and sensitive determination of clozapine in human plasma using high-performance liquid chromatography and amperometric detection. J Chromatogr 1989;491: 235-239.
29. Wilhelm D, Kemper A. High-performance liquid Chromatographic procedure for the determination of clozapine, haloperidol, droperidol and several benzodiazepines in plasma. J Chromatogr 1990; 525:218-224.
30. Gold R, Sponheim B, Sohr R. Serumkonzentration von Clozapin bei Alemoxan-Therapie. Zeitschrift für klinische Medizin 1990;45: 2039-2042.
31. Lovdahl MJ, Perry PJ, Miller DD. The assay of clozapine and N-desmethylclozapine in human plasma by high-performance liquid chromatography. Ther Drug Monit 1991;13:69-72.
32. Chung MC, Lin SK, Chang W, Jann MW. Determination of clozapine and desmethylclozapine in human plasma by high-performance liquid chromatography with ultraviolet detection. J Chromatogr 1993;613:168-173.
33. Olesen OV, Poulsen B. On line fully automated determination of clozapine and desmethylclozapine in human serum by solid-phase extraction on exchangeable cartridges and liquid chromatography using a methanol buffer mobile phase on unmodified silica. J Chromatogr 1993;622:39-46.
34. McCarthy PT, Hughes S, Paton C. Measurement of clozapine and norclozapine in plasma/serum by high performance liquid chromatography with ultraviolet detection. Biomed Chromatogr 1995;9: 36-41.
35. Gupta RN. Column liquid Chromatographic determination of clozapine and N-desmethylclozapine in human serum using solid-phase extraction. J Chromatogr 1995;673:311-315.
36. Little CJ, Stahel O, Hales K. The role of column switching in analyzing complex samples. Int J Environ Anal Chem 1984;18: 11-23
37. Dadgar D, Power A. Application of column-switching technique in biopharmaceutical analysis: I. High performance liquid Chromatographic determinations of amitriptytiline and its metabolites in human plasma. J Chromatogr 1987;416:99-109.
38. Berg JD, Buckley BM. Rapid measurement of anticonvulsant drug concentrations in the out patient clinic using HPLC with direct injection of plasma. Ann Clin Biochem 1987;24:488-493.
39. Matsumoto K, Kikuchi H, Kan S, Iri H, Taahashi H, Umino M. Automated determination of drugs in serum by liquid chromatography with column-switching: I. Separation of antiepileptic drugs and metabolites. Clin Chem 1988;34:141-144.
40. Matsumoto K, Kanba S, Kubo H, Yagi G, Iri H, Yuki H. Automated determination of drugs in serum by liquid chromatography with column-switching: IV. Separation of tricyclic antidepressants and their metabolites. Clin Chem 1989;35:453-456.
41. Härtter S, Hiemke C. Column switching and on-line high-performance liquid chromatography in the analysis of amitriptyline, nortriptyline and hydroxylated metabolites in human plasma or serum. J Chromatogr 1992a;578:273-282.
42. Härtter S, Wetzel H, Hiemke C. Automated determination of fluvoxamine in plasma by column-switching high-performance liquid chromatography. Clin Chem 1992b:38:2082-2086.
43. Härtter S, Hermes B, Szegedi A, Hiemke C. Automated determination of paroxetine and its main metabolite by column switching and on-line high-performance liquid chromatography. Ther Drug Monit 1994;16:400-406.
44. Härtter S, Hermes B, Hiemke C. Automated determination of trimipramine and N-desmethyltrimipramine in human plasma or serum by HPLC with on-line solid phase extraction. J Liquid Chromatogr 1995;18:3495-3505.
45. Pippenger CE. Commentary: therapeutic drug monitoring in the 1990s. Clin Chem 1989;35:1348-1351.
46. Hiemke C. Therapeutisches Drug monitoring von Antidepressiva und Neuroleptika. Psychophammkotherapie 1995;2:21-23.
47. Grohmann R, Rüther E, Sassim N, Schmidt LG. Adverse effects of clozapine. Psychopharmacol 1989;99:101-104.
48. Markowitz JS, Patrick KS. Thermal degradation of clozapine-N-oxide to clozapine during gas Chromatographic analysis. J Chromatogr 1995;668:171-174.
49. Lin G, McKay G, Hubbard JW, Midha KK. Decomposition of clozapine N-oxide in the qualitative and quantitative analysis of clozapine and its metabolites. J Pharm Sci 1994;83:1412-1417.
50. Ackenheil M, Bräu H, Burckhart A, Franke A, Pacha W. Antipsychotische Wirksamkeit im Verhältnis zum Plasmaspiegel von Clozapin. Arzneimittelforschung 1976;26:1156-1158.
51. Haring C, Fleischhacker WW, Schett P, Humpel C, Barnas C, Saria A. Influence of patient-related variables on clozapine plasma levels. Am J Psychiatry 1990;147:1471-1475.
52. Dahl M-L, Bertilsson L, Johansson I, Lundquist E, Ingelmann Sundberg M, Sjöquist F. Molecular aspects of genetic polymorphisms in drug oxidation. Neuropsychopharmacology 1994;10: 488S.
53. Caraco Y, Tateishi T, Wood AJ. Interethnic difference in omeprazole's inhibition of diazepam metabolism. Clin Pharm Ther 1995; 58:62-72.
54. Luo H, Hawes EM, McKay G, Korchinski ED, Midha KK. N(+)-glucoronidation of aliphatic tertiary amines in human: antidepressant versus antipsychotic drugs. Xenobiotica 1995;25:291-301.
55. Stock B, Spiteller G, Heipertz R. Austausch aromatisch gebundenen Halogens gegen OH- und SCH3- bei der Metabolisierung des Clozapins im menschlichen Körper. Arzneimittelforschung 1977;27:982-990.
56. Pirmohamed M, Williams D, Madden S, Templeton E, Park KE. Metabolism and bioactivation of clozapine by human liver in vitro. J Pharmacol Exp Therap 1995;272:984-990.